secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2025-08-15T23:59:59+00:00
Accession:  0001641172-25-024338
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Fertility Q2 2025 revenue up 1% to record $1.86M, net loss widens to $3.2M
-------------------------------------------------------------------------------

- Q2 2025 revenue $1,863,654 (record), up 1% YoY; clinic revenue $1,832,094 up 1%.
- Net loss from continuing operations $(3.2)M vs $(2.2)M in Q2 2024.
- Adjusted EBITDA $(587,230) vs $(509,623) in prior year period.
- Completed divestiture of majority stake in NAYA Therapeutics; retains minority position.
- Launched telehealth and PRP therapy at Wisconsin clinic; received patent allowance for INVOcell device through 2040.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/0001641172-25-024338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225024338/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-024338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer